Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06219161
Other study ID # U0001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2, 2023
Est. completion date July 31, 2023

Study information

Verified date January 2024
Source University of Memphis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of the study is to determine the acute and short-term supplementation effect of a commercially available theacrine-containing supplement (NAD3) on numbers of various circulating stem cell populations in older adults.


Description:

This is a double-blind, placebo-controlled crossover study with 12 participants randomized to receive either NAD3® or a placebo for seven days. Blood samples are collected after an overnight fast, before and after the seven-day supplementation period, as well as one and two hours after the final supplement/placebo dose. Using flow cytometry, circulating stem cells, including lymphocytoid CD34+ stem cells (CD45dimCD34+), stem cells associated with vascular maintenance and repair (CD45dimCD34+CD309+), CD34+ stem cells linked to a progenitor phenotype (CD45dimCD34+CD309neg), circulating endothelial stem cells (CD45negCD31+CD309+), and mesenchymal stem cells (CD45negCD90+) are quantified.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date July 31, 2023
Est. primary completion date June 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria: - Male or Female - Age 40-70 - BMI between 21-34.99 kg/m2 - Vital signs with in normal range (heart rate 60-100 beats/minute, blood pressure (40-44 years - 125/83, 45-49 years- 127/84, 50-54 years -129/85, 55-59 years - 131/86, >60 - 134/87), 36.4-37.4 degrees Celsius - Sedentary to lightly active (2 or fewer days per week of exercise) Exclusion Criteria: - Female participants who are lactating, pregnant or planning to become pregnant during the study - History of use of illicit drugs or other substances of abuse within 12 months of the screening visit (to be determined at screening) - Tobacco during the 90 days prior to screening - Current use of medication/dietary supplements that claim to or have an effect on age-related processes, e.g. "anti-aging" supplements. Participants must undergo a =7-day washout period of no supplementation to be eligible. - Known allergy, intolerance or hypersensitivity to NAD3 - Self-reported active infection or illness of any kind - Cognitively impaired and/or unable to give informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
NAD3
NAD3 supplement (per capsule): 344 mg microcrystalline cellulose,156 mg of a proprietary blend of Wasabia japonica (freeze-dried rhizome) cultivar, standardized to NLT 12,000 ppm isothiocyanates, 97.0% Theacrine, Copper Nicotinic Acid chelated complex (17-20% Copper by ICP-Mass spectroscopy)

Locations

Country Name City State
United States The University of Memphis Memphis Tennessee

Sponsors (2)

Lead Sponsor Collaborator
University of Memphis Compound Solutions Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of stem cell numbers in blood circulation. Flow cytometry evaluation of stem cell phenotype. Changes at 1 and 2 hours after consumption of study product.
Secondary Change to numbers of circulating HSC- CD45, CD34, CD133. Flow cytometry evaluation of stem cell phenotype. Changes at 1 and 2 hours after consumption of study product.
Secondary Change to numbers of circulating CEC - CD45, CD31, CD309. Flow cytometry evaluation of stem cell phenotype. Changes at 1 and 2 hours after consumption of study product.
Secondary Change to numbers of circulating MSC-CD45, CD31, CD90. Flow cytometry evaluation of stem cell phenotype. Changes at 1 and 2 hours after consumption of study product.
See also
  Status Clinical Trial Phase
Withdrawn NCT03629015 - Safety Study of Stemchymal® in Acute Liver Failure Phase 1
Not yet recruiting NCT04998461 - Impact of Obesity, Chronic Kidney Disease and Type 2 Diabetes on Human Urinary Stem Cells
Completed NCT04132531 - Effect of Weight Loss Surgery on Stem Cells.
Completed NCT03381599 - Stem Cells After Peripheral Mobilization and Harvest Phase 1
Completed NCT02697682 - Treatment of Osteoarthritis With the Stromal Vascular Fraction of Abdominal Adipose Tissue - a Pilot Study N/A
Active, not recruiting NCT03874572 - Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth Phase 1
Not yet recruiting NCT03361631 - Intracavernous Injection of Autologous Mesenchymal Stem Cells in the Treatment of Erectile Dysfunction Resistant to Oral Treatment in Patients With Type I Diabetes Phase 1
Not yet recruiting NCT03983902 - Placental Transfusion Methods and Stem Cells N/A
Completed NCT04713436 - The Effects of Antibiotic Combinations on Stem Cells
Active, not recruiting NCT03028428 - Intra-articular Injection of MSCs in Treatment of Knee OA Phase 2
Recruiting NCT04646603 - MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients Phase 2
Withdrawn NCT02677350 - AlloGeneic Human Mesenchymal Stem Cells (hMSC) in PAtients With FistuLizing Crohn's Disease Via PErifistula iNjEctions (GALENE) Phase 1
Completed NCT00340392 - Isolation and Characterization of Mammary Stem Cells N/A
Terminated NCT00316069 - Stem Cell Collection